ev3 Inc. Announces Completion of Patient Enrollment in DURABILITY II Study

PLYMOUTH, Minn., April 26, 2010 (GLOBE NEWSWIRE) -- ev3 Inc. (Nasdaq:EVVV) today announced the completion of patient enrollment in the DURABILITY II trial, a prospective, multi-center, single-arm study evaluating the EverFlex® Self-Expanding Stent System for the treatment of superficial femoral artery (SFA) and proximal popliteal lesions. The DURABILITY II study will support a planned Premarket Approval (PMA) filing with the U.S. Food and Drug Administration to obtain approval of the EverFlex Self-Expanding Stent System for use in the SFA.